2024 Publications



About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

Spherix Provides Independent Expertise in Six Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications		
MARKET DYNAMIX	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.	
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.	
LAUNCH DYNAMI/	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.	
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.	
SPECIAL TOPI/	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.	

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



2024 Dermatology Publications



Atopic Dermatitis		
REALTIME DYNAMI/	Atopic Dermatitis, USAtopic Dermatitis, EU5NPs/PAs, US	
LAUNCH DYNAMIX	 Lebrikizumab (Eli Lilly) in Atopic Dermatitis, US* Nemolizumab (Galderma) in Atopic Dermatitis, US* 	
PATIENT CHART DYNAMI/	Atopic Dermatitis, USAtopic Dermatitis, EU5	
SPECIAL TOPIX	Topical Small Molecules in Atopic Dermatitis, US	

Plaque Psoriasis		
REALTIME DYNAMI/	Plaque Psoriasis, USPlaque Psoriasis, EU5	
LAUNCH DYNAMI/	 Bimzelx (UCB) in Plaque Psoriasis, US Sotyktu (BMS) in Plaque Psoriasis, US Vtama (Dermavant) in Plaque Psoriasis, US Zoryve (Arcutis) in Plaque Psoriasis, US 	
PATIENT CHART DYNAMI/	New Starts + Switching in Plaque Psoriasis, US	
SPECIAL TOPIX	Pre-biologics in Plaque Psoriasis, US	

Alopecia Areata		
MARKET DYNAMI/	Alopecia Areata, US	
LAUNCH DYNAMIX	 Deuruxolitinib (SUN Pharma) in Alopecia Areata, US* Litfulo (Pfizer) in Alopecia Areata, US 	

Hidradenitis Suppurativa		
MARKET DYNAMI/	Hidradenitis Suppurativa, US	
REALTIME DYNAMIX	Hidradenitis Suppurativa, EU5	
LAUNCH DYNAMI/	 Cosentyx (Novartis) in Hidradenitis Suppurativa, US Bimzelx (UCB) in Hidradenitis Suppurativa, US 	
PATIENT CHART DYNAMIX	Hidradenitis Suppurativa, US	

	Other Dermatology
MARKET DYNAMI/	Prurigo Nodularis, USVitiligo, US
LAUNCH DYNAMIX	 Dupixent (Sanofi/Regeneron) in Prurigo Nodularis, US Nemolizumab (Galderma) in Prurigo Nodularis, US* Opzelura (Incyte) in Vitiligo, US
SPECIAL TOPI/	Biologic Coordinators Across Dermatology, US

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
(e)	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
*	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2024 Gastroenterology Publications



Inflammatory Bowel Disease		
REALTIME DYNAMI/	 Crohn's Disease, US Crohn's Disease, EU5 Ulcerative Colitis, US Ulcerative Colitis, EU5 	
LAUNCH DYNAMI/	 Rinvoq (AbbVie) in Crohn's Disease, US Skyrizi (AbbVie) in Crohn's Disease, US Omvoh (Eli Lilly) in Ulcerative Colitis, US Skyrizi (AbbVie) in Ulcerative Colitis, US Velsipity (Arena) in Ulcerative Colitis, US* 	
PATIENT CHART DYNAMI/	 Inflammatory Bowel Disease New Starts, US Inflammatory Bowel Disease Switching, US Inflammatory Bowel Disease New Starts, EU 	

Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis		
MARKET DYNAMI/	• MASLD/MASH, US	
LAUNCH DYNAMIX	Resmetirom (Madrigal) in MASLD/MASH*	
PATIENT CHART DYNAMI/	• MASLD/MASH, US	

General Gastroenterology		
MARKET DYNAMI/	Irritable Bowel Syndrome - Constipation, US	
LAUNCH DYNAMIX	Rebyota (Ferring) and Vowst (Seres) in Clostridium Difficile Infection, US	

Eosinophilic Esophagitis	
MARKET DYNAMI/	Eosinophilic Esophagitis, US
LAUNCH DYNAMIX	• TAK-721 (Takeda) in Eosinophilic Esophagitis*
PATIENT CHART DYNAMI/	Eosinophilic Esophagitis, US

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas



2024 Rheumatology Publications



Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

REALTIME DYNAMI/	 Ankylosing Spondylitis & Non-Radiographic Axia. Spondyloarthritis, US Ankylosing Spondylitis & Non-Radiographic Axia. Spondyloarthritis, EU5
LAUNCH DYNAMI/	Bimzelx (UCB) in Ankylosing Spondylitis, US*

Psoriatic Arthritis		
REALTIME DYNAMI/	 Psoriatic Arthritis, US Psoriatic Arthritis, EU5	
LAUNCH DYNAMIX	Bimzelx (UCB) in Psoriatic Arthritis, US	
PATIENT CHART DYNAMI/	Triggers and Drivers in Psoriatic Arthritis Switching, US	

Lupus	
REALTIME DYNAMI/	 Lupus Nephritis, US Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus, EU5
PATIENT CHART DYNAMIX	Lupus Nephritis, USSystemic Lupus Erythematosus, USSystemic Lupus Erythematosus, EU5

	General Rheumatology	
MARKET DYNAMI∕	 Antineutrophilic Cytoplasmic Antibody (ANCA) Associated Vasculitis, US Dermatomyositis, US Giant Cell Arteritis, US Polymyalgia Rheumatica, US Scleroderma, US 	
REALTIME DYNAMIX	Rheumatoid Arthritis, US	
LAUNCH DYNAMI/	Kevzara (Sanofi/Regeneron) in Polymyalgia Rheumatica, US	
SPECIAL TOPIX	American College of Rheumatology (ACR) Convergence Feedback, US	

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
Z V	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas

2024 Nephrology Publications



Kidney Disease		
MARKET DYNAMI/	 Autosomal Dominant Polycystic Kidney Disease, US Chronic Kidney Disease - Cardiorenal, US End-Stage Kidney Disease Modalities (Dialysis and Transplant), US 	
REALTIME DYNAMIX	 Chronic Kidney Disease/Diabetic Kidney Disease, US Dialysis, US 	
PATIENT CHART DYNAMI/	 Chronic Kidney Disease, Non-Dialysis, US Chronic Kidney Disease, Non-Dialysis, PCP, US Dialysis, US 	
SPECIAL TOPIX	ASN Kidney Week Conference, USBuy and Bill in Nephrology Practices	

	Kidney Disease		Glomerular Diseases
MARKET DYNAMI/	 Autosomal Dominant Polycystic Kidney Disease, US Chronic Kidney Disease - Cardiorenal, US End-Stage Kidney Disease Modalities (Dialysis and Transplant), US 	MARKET DYNAMI/	 Complement Disorders, US Focal Segmental Glomerulosclerosis, US Membranous Nephropathy, US Rare Glomerular Diseases, Japan Rare Glomerular Diseases, EU5
REALTIME DYNAMI/	Chronic Kidney Disease/Diabetic Kidney Disease, USDialysis, US	REALTIME DYNAMI/	• IgA Nephropathy, US
		LAUNCH DYNAMI/	• Filspari (Travere) in IgA Nephropathy, (US)
PATIENT CHART DYNAMI/	 Chronic Kidney Disease, Non-Dialysis, US Chronic Kidney Disease, Non-Dialysis, PCP, US Dialysis, US 	PATIENT CHART DYNAMIX	 Complement 3 Glomerulopathy, EU5 IgA Nephropathy, US IgA Nephropathy, EU5
SPECIAL TOPIX	 ASN Kidney Week Conference, US Buy and Bill in Nephrology Practices 		

Bone and Mineral Metabolism		
LAUNCH	 Xphozah (Ardelyx) in Hyperphosphatemia, US Xphozah (Ardelyx) in Hyperphosphatemia, Renal	
DYNAMI/	Dietitians, US	

	Lupus
REALTIME DYNAMI/	• Lupus Nephritis, US
PATIENT CHART DYNAMIX	• Lupus Nephritis, US

Renal Anemia		
REALTIME DYNAMI/	Renal Anemia, EU5	
LAUNCH DYNAMIX	Jesduvroq (GSK) in Renal AnemiaVadadustat (Akebia) in Renal Anemia	

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
ע	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2024 Neurology Publications



Generalized Myasthenia Gravis		
MARKET DYNAMI/	Generalized Myasthenia Gravis, US	
REALTIME DYNAMIX	Generalized Myasthenia Gravis, EU5	
LAUNCH DYNAMI/	SC Vyvgart Hytrulo (Argenx), Rystiggo (UCB) and Zilucoplan (UCB) in Generalized Myasthenia Gravis, US	
PATIENT CHART DYNAMIX	General Myasthenia Gravis, US	

Migraine	
REALTIME DYNAMI/	Migraine, US
LAUNCH DYNAMIX	Zavzpret (Pfizer) in Acute Migraine, US

Alzheimer's Disease	
MARKET DYNAMI/	Alzheimer's Disease, US
REALTIME DYNAMIX	Alzheimer's Disease, EU5
LAUNCH DYNAMI/	 Donanemab (Lilly) in Alzheimer's Disease, US* Leqembi (Eisai/Biogen)in Alzheimer's Disease, US
PATIENT CHART DYNAMIX	Alzheimer's Disease, US
SPECIAL TOPI/	Alzheimer's Disease Modifying Therapies vs. Symptomatics, US

Multiple Sclerosis	
REALTIME DYNAMI/	Multiple Sclerosis, US
LAUNCH DYNAMIX	 Briumvi in Relapsing Multiple Sclerosis SC Ocrelizumab in Multiple Sclerosis*

General Neurology & Neurodegeneration

MARKET DYNAMI/	 Amyotrophic Lateral Sclerosis, US Chronic Inflammatory Demyelinating Polyneuropathy, US Epilepsy, US Huntington's Disease, US Parkinson's Disease, US Post-Acute Stroke, US
LAUNCH DYNAMIX	Relyvrio (Amylyx) in Amyotrophic Lateral Sclerosis
SPECIAL TOPI/	Evolving Therapies in Parkinson's Disease, US

(ey	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
—	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2024 Ophthalmology Publications



Neovascular Age-Related Macular Degeneration	
REALTIME DYNAMI/	 Neovascular Age-Related Macular Degeneration, US Neovascular Age-Related Macular Degeneration, EU5
LAUNCH DYNAMIX	 Eylea HD (Regeneron/Bayer) in Neovascular Age- Related Macular Degeneration and Diabetic Macular Edema, US
PATIENT CHART DYNAMI/	Neovascular Age-Related Macular Degeneration - Switching, US

	Other Ophthalmology
MARKET DYNAMI/	Diabetic Retinopathy, USGeographic Atrophy, US
LAUNCH DYNAMIX	Syfovre and Izervay in Geographic Atrophy, US
SPECIAL TOPI/	Gene Therapies in Retina, US

Diabetic Macular Edema	
REALTIME DYNAMI/	Diabetic Macular Edema, US
LAUNCH DYNAMIX	Eylea HD (Regeneron/Bayer) in Neovascular Age- Related Macular Degeneration and Diabetic Macular Edema, US
PATIENT CHART DYNAMI/	Diabetic Macular Edema, US



Visit The Spherix Portal



